Kenvue Inc. (NYSE:KVUE) Receives $24.42 Average PT from Analysts

Kenvue Inc. (NYSE:KVUE) has been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $24.42.

Several research analysts have issued reports on KVUE shares. Barclays dropped their price target on Kenvue from $23.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, April 14th. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target on the stock. Citigroup lifted their target price on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Finally, Canaccord Genuity Group lifted their price target on Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, March 5th.

Institutional Investors Weigh In On Kenvue

Several institutional investors and hedge funds have recently bought and sold shares of the business. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. increased its position in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Pittenger & Anderson Inc. bought a new position in shares of Kenvue in the first quarter worth about $30,000. Finally, Fortitude Family Office LLC lifted its position in shares of Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of KVUE opened at $23.95 on Tuesday. The firm has a market capitalization of $45.94 billion, a PE ratio of 45.18, a P/E/G ratio of 2.62 and a beta of 1.02. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $23.08 and a 200 day moving average price of $22.49. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts anticipate that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.42%. Kenvue’s payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.